WO2002004620A2 - Verfahren zur isolierung von nukleinsäuren - Google Patents
Verfahren zur isolierung von nukleinsäuren Download PDFInfo
- Publication number
- WO2002004620A2 WO2002004620A2 PCT/EP2001/008066 EP0108066W WO0204620A2 WO 2002004620 A2 WO2002004620 A2 WO 2002004620A2 EP 0108066 W EP0108066 W EP 0108066W WO 0204620 A2 WO0204620 A2 WO 0204620A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acids
- solution
- nacl
- isopropanol
- concentration
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
Definitions
- the present invention relates to a method for isolating nucleic acids from a solution, the nucleic acids being adsorbed on a Si0 2 -containing surface.
- the present invention relates to the use of a buffer solution for isolating nucleic acids on a support containing SiO 2 and to a kit for carrying out a method for isolating nucleic acids from a solution.
- EP 0389063 B1 relates to a method for isolating nucleic acids from a biological source.
- the biological sources containing nucleic acids such as blood, cells, plasma, etc.
- the nucleic acids are then attached bound a silica surface. These are then washed and eluted.
- the biological sample is acidified and treated with a chaotropic agent, e.g. mixed with a guanidinium salt.
- a chaotropic agent e.g. mixed with a guanidinium salt.
- Silicate particles are added to the sample and, under the given conditions, RNA binds to the silicate particles. Subsequently, the RNA is also separated from the particles here.
- Colpan et al. in WO 95/01359 disclose a process for the purification and separation of nucleic acid mixtures by adsorption of the nucleic acid from an alcohol-containing solution with a high ionic strength.
- the adsorption solution contains salts in a concentration of 1 to 10 M, the chaotropic salts, e.g. Guanidinium thiocyanate, sodium perchlorate, or guanidinium hydrochloride are preferred.
- WO 95/21849 relates to a method for separating double-stranded and / or single-stranded nucleic acids from sources which contain these nucleic acids.
- the nucleic acids are adsorbed on mineral carriers under conditions which allow binding of the desired nucleic acid species, while the undesired nucleic acid species does not bind on this mineral carrier.
- the non-adsorbed double-stranded nucleic acid can then be further purified or isolated using known methods.
- nucleic acids that are used for molecular biological applications are subject to very high requirements in terms of purity and integrity.
- the use of nucleic acids in molecular diagnostics or molecular medicine presupposes that they must be free of toxic substances, which can lead, for example, to pathogenic effects in the organisms to be treated.
- chaotropic salts are used in high concentrations for the isolation of nucleic acids on silica surfaces.
- Chaotropic substances such as guanidinium hydrochloride, guanidinium thiocyanate or sodium perchlorate are highly toxic substances. It cannot be ruled out that the nucleic acids isolated in the presence of these substances will be contaminated with them and thus cannot be used or can only be used to a limited extent for use in molecular biological applications.
- chaotropic substances also represents a high health risk for the user, so that the handling of these substances must be carried out under certain protective measures.
- the technical problem on which the present invention is based is to provide an improved method which uses known disadvantages overcome.
- the substances used in this method for binding the nucleic acid should not be toxic.
- the method should be as inexpensive as possible, for example by using inexpensive chemicals, and the isolated nucleic acids should be isolated quantitatively and qualitatively purely.
- the present invention provides a method for isolating nucleic acids from a solution which achieves this object.
- the invention consists in the fact that in a first step the binding of nucleic acids to Si0 2 -containing surfaces in the presence of alkali halides in a concentration of 0.1-3M, preferably 0.25-1.5M, and alcohol in a concentration from 37 to 70 vol.% is carried out.
- the nucleic acids adsorbed on the Si0 2 -containing surface are then optionally washed with an alcohol-containing washing buffer and the nucleic acid is eluted with an aqueous salt solution or with water.
- Aqueous adsorption solutions are used to bind the nucleic acids to the Si0 2 -containing surface, the alkali halides such as NaCl, KCl and LiCl in a concentration of 0.1-3M, preferably 0.25-1.5M, particularly preferably 0.5 - 1, 25 M and in particular 0.5 - 1, 0 M included.
- Alkali halides are non-toxic substances and handling the salt solutions in the concentration used is harmless to health.
- the aqueous adsorption solutions contain lower aliphatic, branched or unbranched alcohols with a chain length of 1 to 5 carbon atoms.
- the aliphatic alcohols present in the solution are preferably methanol, ethanol, propanol, isopropanol and butanol in a concentration of 37-70% by volume, preferably 37-50% by volume.
- ethanol and / or isopropanol in a concentration of 37-70% by volume are particularly preferred.
- Si0 2 -containing surfaces can, for example, be porous or non-porous silicon oxides or metal-silicon mixed oxides, silica gels, materials
- Base of glasses e.g. modified or unmodified glass particles or glass powder, quartz, zeolites or mixtures of one or more of the substances mentioned above.
- a surface is understood to mean any microporous separating layer.
- the Si0 2 -containing surface is a porous membrane or a process
- Filters made of silica gel, glass or quartz fibers made of silica gel, glass or quartz fibers.
- the term surface in the broader sense also includes a layer of particles or also a granulate and also fibers, such as, for. B. silica gel nonwovens.
- water or aqueous salt solutions are suitable as eluents for eluting the bound nucleic acid.
- Buffer solutions known from the prior art are used as salt solutions, such as, for example, morpholinopropanesulfonic acid (MOPS), tris (hydroxymethyl) aminomethane (TRIS), 2- [4- (2-hydroxyethyl) -1-piperazino] ethanesulfonic acid (HEPES) in a concentration of 0.001 to 0.5 mol / liter, preferably 0.01 to 0.2 mol / liter, particularly preferably 0.01 to 0.05 molar solutions.
- MOPS morpholinopropanesulfonic acid
- TMS tris (hydroxymethyl) aminomethane
- HEPES 2- [4- (2-hydroxyethyl) -1-piperazino] ethanesulfonic acid
- the nucleic acids in the eluate can preferably be isolated by alcoholic precipitation.
- the nucleic acids isolated with this method are free of toxic substances and are therefore suitable for use in molecular biology.
- the term "nucleic acid” is to be understood in its broadest sense, that is to say ribonucleic acids (RNA) as well as deoxyribonucleic acids (DNA) in all lengths and configurations, such as double-stranded, single-stranded, circular and linear, branched, etc.
- nucleic acids such as monomeric nucleotides, oligomers, plasmids, cosmids, viral and bacterial DNA and RNA, as well as genomic and non-genomic DNA and RNA from animal and plant cells or other eukaryotes, mRNA in processed and unprocessed form, tRNA, hn-RNA, rRNA, cDNA and include all other conceivable nucleic acids.
- the method according to the invention allows nucleic acids of any origin to be isolated from solutions.
- the sample containing nucleic acids comes, for example, from animal or vegetable tissues, tissue or cell cultures, bone marrow, human and animal body fluids such as blood, serum, plasma, urine, sperm, cerebrospinal fluid, sputum and smears, plants, plant parts and extracts, for example Juices, mushrooms, prokaryotic or eukaryotic microorganisms such as bacteria or yeast, fossil or mummified samples, soil samples, sewage sludge, waste water and food (especially processed, ie technically processed food).
- Nucleic acids which have arisen from chemical reactions such as, for example, those which have been obtained by polymerase chain reaction (PCR) or plasmid DNA, genomic DNA and RNA and / or nucleic acids which come from microorganisms, can also be isolated according to the invention.
- the method according to the invention is particularly suitable for isolating plasmid DNA from bacteria, such as, for example, E. coli, for subsequent cloning, transfection or sequencing.
- the bacteria are lysed using known lysis methods, such as alkaline lysis according to Bimboim and Doly (1979) or lysis by heating according to Holmes and Quigley.
- the cell debris as well as the precipitated proteins and the genomic DNA are removed from the viscous lysate by centrifugation or filtration, and a clarified lysate is obtained which contains the plasmid DNA.
- the plasmid DNA can be purified, for example, by means of ion exchange chromatography, and the plasmid DNA pre-purified in this way can then be isolated using the method according to the invention.
- Another object of the present invention is a kit for isolating nucleic acids from a solution, comprising a) an adsorption solution containing 0.25-1.5 M NaCl, KCI or a mixture thereof and ethanol or isopropanol in one
- the Si0 2 -containing surface can be a porous membrane or a filter made of silica gel, glass or quartz fibers and arranged in a suitable device.
- the kit preferably also contains solutions suitable for lysis and, as described above, washing and elution buffers.
- nucleic acids isolated according to the invention are free from ; nucleic acid degrading enzymes and have such a high purity, that they can be processed and processed immediately in a variety of ways.
- the nucleic acids produced according to the invention can be used for cloning and serve as substrates for a wide variety of enzymes, such as, for example, DNA polymerases, DNA restriction enzymes, DNA ligase and reverse transcriptase.
- enzymes such as, for example, DNA polymerases, DNA restriction enzymes, DNA ligase and reverse transcriptase.
- the nucleic acids provided by the method according to the invention are particularly well suited for amplification, in particular for PCR, strand displacement amplification, rolling circle methods, ligase chain reaction (LCR) and similar methods.
- the method according to the invention is furthermore particularly suitable for providing nucleic acids for use in diagnostics, in particular for a diagnostic method, which is characterized in that the nucleic acid purified by the method according to the invention is amplified in a subsequent step and subsequently and / or simultaneously the nucleic acid amplified in this way is detected (e.g. Holland, PM et al., 1991. Proc. Natl. Acad. Sci. 88, 7276-7280. Livak, KJ et al., 1995. PCR Methods Applic. 4, 357 - 362; Kievits, T. et al., 1991. J. Virol. Meth. 35, 273-286; Uyttendaele, M. et al., 1994. J. Appl. Bacteriol. 77, 694-701).
- each of the individual buffers (0.25-1.5 M NaCl; 50 mM Tris, pH 8.5; 15% (w / v) isopropanol) were mixed with 10 ⁇ g plasmid DNA (pCMVß; Fa.
- the batches were transferred to a column containing a silica membrane (QIAquick, QIAGEN GmbH, # 28104) and under vacuum (approx. 600 mbar; use of the QIAvac 6S from QIAGEN GmbH) through the silica membrane.
- the mixture was then washed with 750 ⁇ l of buffer PE (10 mM Tris, pH 7.5; 80% ethanol) and drawn through the membrane until the air was dry. Elution was carried out by adding 100 ⁇ l of buffer EB (10 mM Tris, pH 8.5) and the yield was determined photometrically at 260 nm.
- the batches were transferred to a column containing a silica membrane and passed through the silica membrane under vacuum (approx. 600 mbar; use of the QIAvac 6S from QIAGEN GmbH).
- the mixture was then washed with 750 ⁇ l of buffer PE (10 mM Tris, pH 7.5; 80% ethanol) and drawn through the membrane until the air was dry.
- Elution was carried out by adding 100 ⁇ l of buffer EB (10 mM Tris, pH 8.5) and the yield was determined photometrically at 260 nm.
- 15 ml buffer Q1 1, 25 M NaCl; 50 mM Tris, pH 8.5; 15 vol% Isopropanol
- isopropanol was added to a final concentration of 49.8% by volume, mixed thoroughly and incubated for 5 minutes on the laboratory bench.
- the DNA / Q1 / isopropanol mixture was transferred to a 20 ml syringe, which was equipped with a syringe filter containing a silica membrane (from Sartorius, Minisart series).
- the recovery rate of the DNA is between 80 and 90% even with higher amounts of plasmid DNA.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01971766A EP1299531A2 (de) | 2000-07-12 | 2001-07-12 | Verfahren zur isolierung von nukleinsäuren |
JP2002509474A JP2004502458A (ja) | 2000-07-12 | 2001-07-12 | 核酸の単離方法 |
US10/332,667 US20040091875A1 (en) | 2000-07-12 | 2001-07-12 | Method for isolating nucleic acids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10033991A DE10033991A1 (de) | 2000-07-12 | 2000-07-12 | Verfahren zur Isolierung von Nukleinsäuren |
DE10033991.3 | 2000-07-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002004620A2 true WO2002004620A2 (de) | 2002-01-17 |
WO2002004620A3 WO2002004620A3 (de) | 2002-07-18 |
Family
ID=7648743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/008066 WO2002004620A2 (de) | 2000-07-12 | 2001-07-12 | Verfahren zur isolierung von nukleinsäuren |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040091875A1 (de) |
EP (1) | EP1299531A2 (de) |
JP (1) | JP2004502458A (de) |
DE (1) | DE10033991A1 (de) |
WO (1) | WO2002004620A2 (de) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004042058A2 (de) * | 2002-11-08 | 2004-05-21 | InViTek Gesellschaft für Biotechnik & Biodesign mbH | Neuartige pufferformulierungen zur isolierung, reinigung und rückgewinnung lang- und kurzkettiger nukleinsäuren |
EP1690938A1 (de) * | 2005-02-11 | 2006-08-16 | Qiagen GmbH | Verfahren zur Isolierung von Nukleinsäuren, wobei die Nukleinsäuren bei erhöhter Temperatur an einer Matrix immobilisiert werden |
WO2007036564A2 (de) | 2005-09-29 | 2007-04-05 | Aj Innuscreen Gmbh | Verfahren und formulierung zur extraktion von nukleinsäuren aus beliebigen komplexen ausgangsmaterialien |
WO2007065934A1 (de) * | 2005-12-07 | 2007-06-14 | Aj Innuscreen Gmbh | Verfahren und testkit zur trennung, aufreinigung und wiedergewinnung von lang- und kurzkettigen nukleinsäuren |
JP2008220380A (ja) * | 2003-10-31 | 2008-09-25 | Fujifilm Corp | 核酸の分離精製方法 |
US10000751B2 (en) | 2011-12-22 | 2018-06-19 | General Electric Company | Method and apparatus for isolating nucleic acids |
EP1654361B2 (de) † | 2003-07-25 | 2023-01-18 | Life Technologies Corporation | Verfahren und zusammensetzungen zur herstellung von rna aus einer fixierten probe |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10253351B4 (de) * | 2002-11-08 | 2007-02-22 | InViTek Gesellschaft für Biotechnik & Biodesign mbH | Neuartige Pufferfomulierungen zur Isolierung, Reinigung und Rückgewinnung lang- und kurzkettiger Nukleinsäuren |
JP5463492B2 (ja) * | 2008-10-08 | 2014-04-09 | 島根県 | 微生物細胞からのプラスミドdna抽出法 |
DE102012012523B4 (de) | 2012-06-26 | 2015-02-12 | Magnamedics Gmbh | Reinigung von Nukleinsäuren |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0512767A1 (de) * | 1991-05-03 | 1992-11-11 | Becton, Dickinson and Company | Festphase-Extraktionsreinigung von DNA |
US5329000A (en) * | 1991-10-31 | 1994-07-12 | Becton, Dickinson And Company | Purification of DNA with silicon tetrahydrazide |
WO1996021729A1 (en) * | 1995-01-13 | 1996-07-18 | Vical Incorporated | Process for reducing rna concentration in a mixture of biological material using diatomaceous earth |
WO1999054340A1 (en) * | 1998-04-22 | 1999-10-28 | Promega Corporation | Endotoxin reduction in nucleic acid purification |
WO2000034463A1 (de) * | 1998-12-04 | 2000-06-15 | Invitek Gmbh | Formulierungen und verfahren zur isolierung von nukleinsäuren aus beliebigen komplexen ausgangsmaterialien und nachfolgende komplexe genanalytik |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5155018A (en) * | 1991-07-10 | 1992-10-13 | Hahnemann University | Process and kit for isolating and purifying RNA from biological sources |
DE4321904B4 (de) * | 1993-07-01 | 2013-05-16 | Qiagen Gmbh | Verfahren zur chromatographischen Reinigung und Trennung von Nucleinsäuregemischen |
ATE210671T1 (de) * | 1994-02-11 | 2001-12-15 | Qiagen Gmbh | Verfahren zur trennung von doppelstrang/einzelstrangnukleinsäurestrukturen |
JP4196227B2 (ja) * | 1997-05-20 | 2008-12-17 | 東洋紡績株式会社 | 核酸またはタンパク質抽出用シリカ粒子組成物 |
JPH11196869A (ja) * | 1998-01-19 | 1999-07-27 | Toyobo Co Ltd | リボ核酸の単離方法 |
ATE530648T1 (de) * | 1999-05-14 | 2011-11-15 | Promega Corp | Zell konzentration und lysat klärung mittels paramagnetischen partikeln |
-
2000
- 2000-07-12 DE DE10033991A patent/DE10033991A1/de not_active Withdrawn
-
2001
- 2001-07-12 JP JP2002509474A patent/JP2004502458A/ja active Pending
- 2001-07-12 EP EP01971766A patent/EP1299531A2/de not_active Ceased
- 2001-07-12 WO PCT/EP2001/008066 patent/WO2002004620A2/de not_active Application Discontinuation
- 2001-07-12 US US10/332,667 patent/US20040091875A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0512767A1 (de) * | 1991-05-03 | 1992-11-11 | Becton, Dickinson and Company | Festphase-Extraktionsreinigung von DNA |
US5329000A (en) * | 1991-10-31 | 1994-07-12 | Becton, Dickinson And Company | Purification of DNA with silicon tetrahydrazide |
WO1996021729A1 (en) * | 1995-01-13 | 1996-07-18 | Vical Incorporated | Process for reducing rna concentration in a mixture of biological material using diatomaceous earth |
WO1999054340A1 (en) * | 1998-04-22 | 1999-10-28 | Promega Corporation | Endotoxin reduction in nucleic acid purification |
WO2000034463A1 (de) * | 1998-12-04 | 2000-06-15 | Invitek Gmbh | Formulierungen und verfahren zur isolierung von nukleinsäuren aus beliebigen komplexen ausgangsmaterialien und nachfolgende komplexe genanalytik |
Non-Patent Citations (1)
Title |
---|
NEUDECKER FRANK ET AL: "High-throughput method for isolating plasmid DNA with reduced lipopolysaccharide content." BIOTECHNIQUES, Bd. 28, Nr. 1, Januar 2000 (2000-01), Seiten 107-109, XP002158615 ISSN: 0736-6205 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004042058A3 (de) * | 2002-11-08 | 2004-08-19 | Invitek Biotechnik & Biodesign | Neuartige pufferformulierungen zur isolierung, reinigung und rückgewinnung lang- und kurzkettiger nukleinsäuren |
WO2004042058A2 (de) * | 2002-11-08 | 2004-05-21 | InViTek Gesellschaft für Biotechnik & Biodesign mbH | Neuartige pufferformulierungen zur isolierung, reinigung und rückgewinnung lang- und kurzkettiger nukleinsäuren |
EP1560926B2 (de) † | 2002-11-08 | 2013-08-21 | STRATEC Molecular GmbH | Neuartige pufferformulierungen zur isolierung, reinigung und rückgewinnung lang- und kurzkettiger nukleinsäuren |
EP1654361B2 (de) † | 2003-07-25 | 2023-01-18 | Life Technologies Corporation | Verfahren und zusammensetzungen zur herstellung von rna aus einer fixierten probe |
JP2008220380A (ja) * | 2003-10-31 | 2008-09-25 | Fujifilm Corp | 核酸の分離精製方法 |
CN101115833B (zh) * | 2005-02-11 | 2012-01-04 | 恰根有限公司 | 分离核酸的方法,该核酸在提高的温度下固定于基质上 |
EP1690938A1 (de) * | 2005-02-11 | 2006-08-16 | Qiagen GmbH | Verfahren zur Isolierung von Nukleinsäuren, wobei die Nukleinsäuren bei erhöhter Temperatur an einer Matrix immobilisiert werden |
WO2006084753A1 (de) * | 2005-02-11 | 2006-08-17 | Qiagen Gmbh | Verfahren zur isolierung von nukleinsäuren, wobei die nukleinsäuren bei erhöhter temperatur an einer matrix immobilisiert werden |
EP3168303A1 (de) * | 2005-02-11 | 2017-05-17 | QIAGEN GmbH | Verfahren zur isolierung von nukleinsäuren, wobei die nukleinsäuren bei erhöhter temperatur an einer matrix immobilisiert werden |
WO2007036564A2 (de) | 2005-09-29 | 2007-04-05 | Aj Innuscreen Gmbh | Verfahren und formulierung zur extraktion von nukleinsäuren aus beliebigen komplexen ausgangsmaterialien |
US8029991B2 (en) | 2005-09-29 | 2011-10-04 | Aj Innuscreen Gmbh | Method and formulation for the extraction of nucleic acids from any complex starting materials |
WO2007036564A3 (de) * | 2005-09-29 | 2007-06-07 | Aj Innuscreen Gmbh | Verfahren und formulierung zur extraktion von nukleinsäuren aus beliebigen komplexen ausgangsmaterialien |
US8735068B2 (en) | 2005-12-07 | 2014-05-27 | Aj Innuscreen Gmbh | Method and test kit comprising citric acid salt and alcohol in a binding buffer for the separation, purification and recycling of long- and short-chain nucleic acids |
WO2007065934A1 (de) * | 2005-12-07 | 2007-06-14 | Aj Innuscreen Gmbh | Verfahren und testkit zur trennung, aufreinigung und wiedergewinnung von lang- und kurzkettigen nukleinsäuren |
US10000751B2 (en) | 2011-12-22 | 2018-06-19 | General Electric Company | Method and apparatus for isolating nucleic acids |
US10683496B2 (en) | 2011-12-22 | 2020-06-16 | General Electric Company | Method and apparatus for isolating nucleic acids |
Also Published As
Publication number | Publication date |
---|---|
EP1299531A2 (de) | 2003-04-09 |
US20040091875A1 (en) | 2004-05-13 |
DE10033991A1 (de) | 2002-01-24 |
JP2004502458A (ja) | 2004-01-29 |
WO2002004620A3 (de) | 2002-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1851313B1 (de) | Verfahren zur isolierung von nukleinsäuren, wobei die nukleinsäuren bei erhöhter temperatur an einer matrix immobilisiert werden | |
EP1146049B1 (de) | Verfahren zur Trennung von Doppelstrang/Einzelstrangnukleinsäurestrukturen | |
DE4321904B4 (de) | Verfahren zur chromatographischen Reinigung und Trennung von Nucleinsäuregemischen | |
EP2501811B1 (de) | Verfahren zur selektiven anreicherung und isolierung mikrobieller und optional zusätzlich viraler nukleinsäuren | |
DE19900638C2 (de) | Methode zur Isolierung von DNA aus biologischen Materialien | |
EP1071691B1 (de) | Verfahren zur isolierung und aufreinigung von nucleinsäuren | |
EP1049801B1 (de) | Verfahren zur isolierung und reinigung von nukleinsäuren an oberflächen | |
WO1995034569A1 (de) | Universelles verfahren zur isolierung und reinigung von nukleinsäuren aus extrem geringen mengen sowie sehr stark verunreinigten unterschiedlichsten ausgangsmaterialien | |
WO2003035903A1 (de) | Verfahren zur isolierung von dna aus biologischen proben | |
EP1771242B1 (de) | Verfahren zur effizienten isolierung von nukleinsäuren | |
EP1560926B1 (de) | Neuartige pufferformulierungen zur isolierung, reinigung und rückgewinnung lang- und kurzkettiger nukleinsäuren | |
WO2002004620A2 (de) | Verfahren zur isolierung von nukleinsäuren | |
EP3228710B1 (de) | Aufreinigung von nukleinsäure aus einer nukleinsäure und endotoxin enthaltenden probe | |
EP1693453B1 (de) | Verfahren zur Isolierung und Trennung von einzel- und doppelsträngigen Nucleinsäuren sowie Trennsäule zur Durchführung des Verfahrens | |
DE10253351A1 (de) | Neuartige Pufferfomulierungen zur Isolierung, Reinigung und Rückgewinnung lang- und kurzkettiger Nukleinsäuren | |
WO1999032616A2 (de) | Verfahren zur isolierung von kurz- und langkettigen nukleinsäuren | |
EP1165579A1 (de) | Verfahren zur herstellung endotoxinfreier nukleinsäuren und deren verwendung | |
DE102005031910B4 (de) | Verfahren zum Stabilisieren von Nukleinsäuren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001971766 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001971766 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10332667 Country of ref document: US |
|
WWR | Wipo information: refused in national office |
Ref document number: 2001971766 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001971766 Country of ref document: EP |